Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Is Jumping Today

By Keith Speights - Jun 28, 2021 at 12:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for Intellia was viewed as good news for Editas.

What happened

Shares of Editas Medicine (EDIT -5.88%) were jumping 7% as of 11:53 a.m. EDT on Monday after rising as much as 20.2% earlier in the day. The gain came after another CRISPR-focused biotech, Intellia Therapeutics (NTLA -7.18%), announced encouraging interim data over the weekend from a phase 1 study of NTLA-2001 in treating rare genetic disease transthyretin (TTR) amyloidosis.

So what

Sympathy moves among biotech stocks happen fairly often. Investors view good news for one company as potentially good news for other companies with similar products in development.

In this case, Intellia's interim results were the first to show safety and efficacy for an in vivo (in the body) CRISPR gene-editing therapy NTLA-2001 in humans. Why might this be viewed as good news for Editas?

DNA image over a person's outstretched palm.

Image source: Getty Images.

Like Intellia, Editas is developing both in vivo and ex vivo (out of the body) CRISPR gene-editing therapies. Intellia's preliminary success with NTLA-2001 raises hopes that Editas will be able to follow suit.

It's important to note, though, that Intellia's results are really early and were only for six patients. Also, the in vivo approaches taken by Intellia and Editas are different. 

Now what

Editas already had some positive news for its lead in vivo CRISPR therapy, EDIT-101, last week. The company announced that the independent data monitoring committee overseeing the phase 1/2 clinical study of the therapy gave a green light to begin testing in children. Editas hopes to report initial data from an adult cohort of the study of EDIT-101 in September. 

Keith Speights owns shares of Editas Medicine. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$16.32 (-5.88%) $-1.02
Intellia Therapeutics Stock Quote
Intellia Therapeutics
NTLA
$59.56 (-7.18%) $-4.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.